ABOS Overview

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is7.00 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Acumen Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

Acumen Pharmaceuticals Inc. EPS for the last quarter amounts to -0.41 USD, decreased -33.87

Acumen Pharmaceuticals Inc (ABOS) has 60 emplpoyees as of March 30 2026.

Today ABOS has the market capitalization of 163.20M USD.